Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $61.77

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $59.13.

A number of research analysts have commented on NTLA shares. Stifel Nicolaus decreased their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Citigroup decreased their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday. Chardan Capital decreased their price objective on Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Robert W. Baird decreased their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $15.95 on Tuesday. The firm has a market cap of $1.62 billion, a PE ratio of -2.91 and a beta of 1.76. Intellia Therapeutics has a one year low of $15.35 and a one year high of $34.87. The stock’s 50 day simple moving average is $20.71 and its 200 day simple moving average is $22.73.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. Intellia Therapeutics’s revenue was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.40) EPS. As a group, equities analysts expect that Intellia Therapeutics will post -5.22 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. raised its stake in Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the period. Elmwood Wealth Management Inc. raised its stake in shares of Intellia Therapeutics by 0.9% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock valued at $1,393,000 after purchasing an additional 600 shares during the period. Interchange Capital Partners LLC lifted its holdings in shares of Intellia Therapeutics by 6.5% in the first quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company’s stock valued at $303,000 after purchasing an additional 670 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Intellia Therapeutics by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock valued at $245,000 after purchasing an additional 750 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.